carboplatin
Showing 51 - 75 of 1,824
Extensive Stage Small Cell Lung Cancer Trial in France ([177Lu]Lu-DOTA-TATE, Tislelizumab, [68Ga]Ga-DOTA-TATE)
Recruiting
- Extensive Stage Small Cell Lung Cancer
- [177Lu]Lu-DOTA-TATE
- +4 more
-
Lille, France
- +6 more
Jan 23, 2023
Triple-negative Breast Cancer Trial in Shanghai (chidamide, camrelizumab, carboplatin)
Not yet recruiting
- Triple-negative Breast Cancer
- chidamide
- +3 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jun 25, 2022
Carcinoma, Small Cell Lung Trial in China (Atezolizumab, Cisplatin, Carboplatin)
Active, not recruiting
- Carcinoma, Small Cell Lung
- Atezolizumab
- +4 more
-
Beijing City, China
- +7 more
Nov 24, 2022
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma
Recruiting
- Fallopian Tube Endometrioid Adenocarcinoma
- +17 more
- Biopsy
- +3 more
-
Augusta, Georgia
- +4 more
Jan 25, 2023
DLBCL (DLBCL) Trial (Glofitamab, Obinutuzumab, Tocilizumab)
Recruiting
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Glofitamab
- +6 more
-
Pembroke Pines, Florida
- +3 more
Jan 23, 2023
SCLC,Extensive Stage Trial in Omaha (RYZ101 Dose Level 1, RYZ101 Dose Level 2, RYZ101 Dose Level 3)
Recruiting
- SCLC,Extensive Stage
- RYZ101 Dose Level 1
- +6 more
-
Omaha, NebraskaNebraska Cancer Specialists
Nov 18, 2022
Breast Cancer Trial in Cincinnati, Houston (Docetaxel, Carboplatin)
NSCLC Trial in Shanghai (Pembrolizumab, Paclitaxel, Nab-paclitaxel)
Active, not recruiting
- Non-small Cell Lung Cancer
- Pembrolizumab
- +4 more
-
Shanghai, ChinaZhongshan Hospital Fudan University
Aug 18, 2022
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Squamous Cell Carcinoma Trial in Philadelphia (Capecitabine,
Active, not recruiting
- Anal Basaloid Carcinoma
- +6 more
- Capecitabine
- +6 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Jan 3, 2023
Solid Tumor Trial (CP-506, Carboplatin, Immune checkpoint inhibitor)
Not yet recruiting
- Unspecified Adult Solid Tumor, Protocol Specific
- CP-506
- +2 more
- (no location specified)
Jun 23, 2022
Triple-negative Breast Cancer Trial in Worldwide (LAG525, Spartalizumab, Carboplatin)
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Seattle
Recruiting
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Carboplatin
- Pembrolizumab
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Mar 10, 2022
Ovarian Tumor Epithelial, Ovarian Cancer, Fallopian Tube Tumors Trial in India (Oregovomab, Paclitaxel, Carboplatin)
Not yet recruiting
- Ovarian Neoplasm Epithelial
- +4 more
- Oregovomab
- +3 more
-
Visakhapatnam, Andhra Pradesh, India
- +7 more
Dec 7, 2022
NSCLC Trial in Gyeonggi-do, Incheon, Seoul (Lazertinib, Pemetrexed, Carboplatin)
Not yet recruiting
- Non-small Cell Lung Cancer
- Lazertinib
- +2 more
-
Gyeonggi-do, Korea, Republic of
- +5 more
Jul 25, 2022
Optic Glioma, Pediatric Brain Tumor, Optic Nerve Glioma Trial in Beijing (Carboplatin, Vincristine, Recombinant human
Recruiting
- Optic Glioma
- Pediatric Brain Tumor, Optic Nerve Glioma
- Carboplatin
- +2 more
-
Beijing, ChinaCapital Medical University Sanbo Brain Hospital
Jul 4, 2022
Solid Tumors, Adult, PIK3CA Mutation-Related Tumors, PIK3CA Mutation Trial in San Francisco (Alpelisib, Carboplatin,
Not yet recruiting
- Solid Tumors, Adult
- +7 more
- Alpelisib
- +3 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jul 21, 2022
HER2-positive Breast Cancer Trial in Shenyang (ARX788, Pyrotinib maleate, Trastuzumab)
Recruiting
- HER2-positive Breast Cancer
- ARX788
- +5 more
-
Shenyang, Liaoning, ChinaShengjing Hospital affiliated to China Medical University
Jun 21, 2022
Head and Neck Squamous Cell Carcinoma Trial in Guangzhou (Nab paclitaxel, Carboplatin, adelbelimumab)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- Nab paclitaxel
- +2 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen Memorial Hospital
Aug 24, 2023
Recurrent NSCLC Trial in Changchun, Shanghai (Cisplatin, Carboplatin, Docetaxel)
Recruiting
- Recurrent Non-small Cell Lung Cancer
- Cisplatin
- +7 more
-
Changchun, Jilin, China
- +2 more
May 3, 2022
NSCLC Trial (Bemcentinib, Pembrolizumab, Pemetrexed)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Bemcentinib
- +3 more
- (no location specified)
Jul 19, 2022
Breast Cancer, TNBC - Triple-Negative Breast Cancer Trial (Toripalimab, Epirubicin, High Intensity Focused Ultrasoun)
Not yet recruiting
- Breast Cancer
- TNBC - Triple-Negative Breast Cancer
- Toripalimab
- +5 more
- (no location specified)
Aug 5, 2022
Non Small Cell Lung Cancer Trial in Tianjin (Osimertinib, Bevacizumab Biosimilar IBI305, Carboplatin)
Recruiting
- Non Small Cell Lung Cancer
- Osimertinib
- +3 more
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Aug 18, 2022
Metastatic Lung Non-Small Cell Squamous Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer
Active, not recruiting
- Metastatic Lung Non-Small Cell Squamous Carcinoma
- +7 more
- Carboplatin
- +2 more
-
Los Angeles, California
- +9 more
Dec 17, 2022